Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 in Patients with Advanced or Metastatic Solid Tumors
NCT #
not yet registered
Condition(s)
Solid Tumor
Molecular Target(s)
CD137, PD-L1
Drug Classification(s)
Bispecific Antibodies, Immunotherapy
Agents(s)
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway.
Phase(s)
I
Mechanism of Action
BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody
Purpose
- How much of the study can be given with an acceptable level of side effects
- The effects of the study (good and bad)
- How much of the study is absorbed into the blood and how fast it is removed
- How the study is acting on your body
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.